Chlamydia antigens and corresponding DNA fragments and uses...

Details Chlamydia antigens and corresponding DNA fragments and uses... Chlamydia antigens and corresponding DNA fragments and uses...

2007-11-20

2007-11-20

Ungar, Susan (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S184100, C424S190100, C424S192100, C514S04400A, C435S069100, C435S069700, C435S070100, C435S071100, C435S071200, C435S254110, C536S023700

Reexamination Certificate

active

09868987

ABSTRACT:
The present invention provides purified and isolated polynucleotide molecules that encodeChlamydiapolypeptides which can be used in methods to prevent, treat, and diagnoseChlamydiainfection. In one form of the invention, the polynucleotide molecules are selected from DNA that encode polypeptides CPN100686 RY 54 (SEQ ID Nos: 1 and 14), CPN100696 RY-55 (SEQ ID Nos: 2 and 15), CPN100709 RY-57 (SEQ ID Nos: 3 and 16), CPN100710 RY-58 (SEQ ID Nos: 4 and 17), CPN100711 RY-59 (SEQ ID Nos: 5 and 18), CPN100877 RY-61 (SEQ ID Nos: 6 and 19), CPN100325 RY-62 (SEQ ID Nos: 7 and 20), CPN100368 RY-63 (SEQ ID Nos: 8 and 21), CPN100624 RY-64 (SEQ ID Nos:9 and 22), CPN100633 RY-65 (SEQ ID Nos:10 and 23), CPN100985 RY-66 (SEQ ID Nos:11 and 24), CPN100987 RY-67 (SEQ ID Nos:12 and 25) and CPN100988 RY-68 (SEQ ID Nos:13 and 26).

REFERENCES:
patent: 6521745 (2003-02-01), Murdin et al.
patent: 6559294 (2003-05-01), Griffais et al.
patent: 6693087 (2004-02-01), Murdin et al.
patent: 6808713 (2004-10-01), Murdin et al.
patent: 6822071 (2004-11-01), Stephens et al.
patent: 7019125 (2006-03-01), Murdin et al.
patent: 7070792 (2006-07-01), Murdin et al.
patent: 7081245 (2006-07-01), Murdin et al.
patent: 2002/0082402 (2002-06-01), Murdin et al.
patent: 2002/0094340 (2002-07-01), Murdin et al.
patent: 2002/0094965 (2002-07-01), Murdin et al.
patent: 2002/0099188 (2002-07-01), Murdin et al.
patent: 2002/0132994 (2002-09-01), Murdin et al.
patent: 2003/0100706 (2003-05-01), Murdin et al.
patent: 2004/0254130 (2004-12-01), Murdin et al.
patent: 0784059 (1997-07-01), None
patent: WO 99/28475 (1999-06-01), None
patent: WO9927105 (1999-06-01), None
patent: WO 00/24765 (2000-05-01), None
patent: WO00/27994 (2000-05-01), None
patent: WO 00/34483 (2000-06-01), None
patent: WO 00/37494 (2000-06-01), None
patent: WO 00/46359 (2000-08-01), None
patent: WO 00/66739 (2000-11-01), None
patent: WO 01/21804 (2001-03-01), None
patent: WO 01/21811 (2001-03-01), None
patent: WO 01/40474 (2001-06-01), None
patent: WO 01/46224 (2001-06-01), None
patent: WO 01/81379 (2001-11-01), None
patent: WO 01/85972 (2001-11-01), None
patent: WO 02/02606 (2002-01-01), None
patent: WO 02/08267 (2002-01-01), None
Rudinger et al, in “Peptide Hormones”, edited by Parsons, J.A., University Park Press, Jun. 1976, p. 6.
Burgess et al., The Journal of Cell Biology, 111:2129-2138, 1990.
Lazar et al., Molecular and Cellular Biology, 8(3): 1247-1252, 1988.
Jobling et al. (Mol. Microbiol. 1991, 5(7): 1755-67.
Boehringer Mannheim Biochemicals (1991 Catalog p. 557).
Stratagene (1991 Product Catalog, p. 66).
Promega (1993/1994 Catalog, pp. 90-91) or.
New England BioLabs (Catalog 1986/1987, pp. 60-62).
Gibco BRL (Catalogue & Reference Guide 1992, p. 292).
Hillier et al (Genome Research. vol. 6, No. 9, pp. 807-828. 1996.
Allen et al, Journal of Immunology 1991, 147; 674-679.
Batteiger et al 1996, Infection and Immunity , 64; 2839-2841.
Murdin et al (J. Infectious Diseases, 2000, 181, Suppl. 3:S552-S557.
Verma et al. (1997) Nature, vol. 389, p. 239.
Miller et al , The FASEB Journal 1995, 9: 190-199).
Niman et al, PNAS, USA1983, vol. 80:4949-4953.
Current Protocols in Immunology, 1997 unit 9.7.1-9.7.5, 9.7.16-9.7.19.
Reece et al, 1994, J. Immunol, vol. 172 , 241.
Grayston et al. (1995)Journal of Infectious Diseases168:1231.
Campos et al. (1995)Investigation of Ophthalmology and Visual Science36:1477.
Grayston et al (1990)Journal of Infectious Diseases161:618.
Marrie (1993)Clinical Infectious Diseases. 18:501.
Wang et al (1986) Chlamydial infectious. Cambridge University Press, Cambridge. p. 329.
Saikku et al. (1988)Lancet;ii:983.
Thom et al. (1992)JAMA268:68.
Linnanmaki et al. (1993),Circulation87:1130.
Saikku et al. (1992)Annals Internal Medicine116:273.
Melnick et al (1993)American Journal of Medicine95:499.
Shor et al. (1992)South African. Medical Journal82:158.
Kuo et al. (1993)Journal of Infectious Diseases167:841.
Kuo et al. (1993)Arteriosclerosis and Thrombosis13:1501.
Campbell et al (1995)Journal of Infectious Diseases172:585.
Chiu et al (1997)Circulation. 96 (7) :2144-2148.
Ramirez et al (1996)Annals of Internal Medicine125:979.
Jackson et al. Abst. K121, p272, 36thICAAC, Sep. 15-18, 1996, New Orleans.
Fong et al (1997)Journal of Clinical Microbiology35:48.
Hahn DL, et al. “Evidence forChlamydia pneumoniaeinfection in steroid-dependent asthma”.Ann Allergy Asthma Immunol. Jan. 1998; 80(1): 45-49.
Hahn DL, et al. “Association ofChlamydia pneumoniaeIgA antibodies with recently symptomatic asthma”.Epidemiol Infect. Dec. 1996; 117(3): 513-517.
Bjornsson E, et al. “Serology of chlamydia in relation to asthma and bronchial hyperresponsiveness”.Scand J Infect Dis. 1996; 28(1): 63-69.
Hahn DL. “Treatment ofChlamydia pneumoniaeinfection in adult asthma: a before-after trial”. J Fam Pract. Oct. 1995; 41(4): 345-351.
Allegra L, et al. “Acute exacerbations of asthma in adults”:role of Chlamydia pneumoniae infection. Eur Respir J. Dec. 1994; 7(12): 2165-2168.
Hahn DL, et al. “Association ofChlamydia pneumoniae(strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma”.JAMA. Jul. 10, 1991; 266(2): 225-230.
Pal et al. (1996)Infection and Immunity. 64:5341.
Jones et al. (1995)Vaccine13:715.
Igietseme et al (1993)Regional Immunology5:317.
Magee et al (1993)Regional Immunology5: 305.
Landers et al (1991)Infection&Immunity59:3774.
Magee et al (1995)Infection&Immunity63:516.
Cotter et al. (1995)Infection and Immunity63:4704.
Campbell et al (1990)Infection and Immunity58:93.
McCafferty et al (1995)Infection and Immunity63:2387-9.
Gaydos et al.; “Similarity ofChlamydia pneumoniaestrains in the Variable Domain IV Region of the Major Outer Membrane Protein Gene”; Infection and Immunity; 60(12):5319-5323. Dec. 1992.
Wiedmann-Al-Ahmad M, et al. “Reactions of polyclonal and neutralizing anti-p54 monoclonal antibodies with an isolated, species-specific 54-kilodalton protein ofChlamydia pneumoniae”. Clin Diagn Lab Immunol. Nov. 1997; 4(6:700-704).
Hughes et al., 1992.Infect. Immun. 60(9): 3497.
Dion et al., 1990.Virology179:474-477.
Snijders et al., 1991.J. Gen. Virol. 72:557-565.
Langeveld et al.,Vaccine12(15):1473-1480, 1994.
Kunkel et al.Proc. Natl. Acad. Sci. USA(1985) 82:488.
Casey & Davidson,Nucl. Acid Res. (1977) 4:1539.
Cagnon et al.,Protein Engineering(1991) 4(7):843.
Takase et al.,J. Bact. (1987) 169:5692.
Perez Melgosa et al.,Infect Immun(1994) 62:880.
Watson et al., Nucleic Acids Res (1990) 18:5299.
Watson et al.,Microbiology(1995) 141:2489.
Melgosa et al., “Outer membrane complex proteins ofChlamydia pneumoniae” FEMS Microbiol Lett., NL, Amsterdam, Sep. 1993; 112(2:199-204).
Campbell et al.,J Clin Microbiol(1990) 28 :1261.
Iijima et al., “Characterization ofChlamydia pneumoniaespecies-specific proteins immunodominant in humans”J Clin Microbiol. Mar. 1994; 32(3:583-588).
Http://chlamydia-www.berkeley.edu:4231/.
Bachmaier et al., Science (1999) 283:1335.
Ausubel et al.; “Current Protocols in Molecular Biology”; John Wiley & Sons Inc., vol. 1; 1993; 15 sheets.
Silhavy et al.; “Experiments with Gene Fusions”; Cold Spring Harbor Laboratory Press; 1984; pp. 191-195.
Davis et al., “A Manual for Genetic Engineering: Advanced Bacterial Genetics” Cold Spring Harbor Laboratory Press; 1980; pp. 174-176.
Database GENEMBL [Online], Jul. 22, 1998, Stephens et al., “Chlamydia trachomatissection 45 of 87 of the complete genome”, XP002133142, Accession AE001318.
Stephens et al., “Genome Sequence of an Obligate Intracellular Pathogen of Humans:Chlamydia trachomatis”, Science, vol. 282, Oct. 23, 1998, pp. 754-759, XP002104802.
Database GENEMBL [Online], Mar. 15, 1999, Kalman et al., “Chlamydia pneumoniaesection 57 of 103 of the complete genome”, XP002133143, Accession AE001641.
Kalman et al., “Comparative Genomes ofChlamydia pneumoniaeand C. trachomatis”,Nature Genetics, vol. 21, Apr. 1999

Affiliated with

Also associated with

Rating

Chlamydia antigens and corresponding DNA fragments and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chlamydia antigens and corresponding DNA fragments and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chlamydia antigens and corresponding DNA fragments and uses... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3823488